TRDA
Entrada TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The company did deliver favorable safety, no serious adverse events, normal kidney markers, and a statistically significant Time to Rise velocity signal in Cohort 1, while management argues the pediatric PK shortfall is now better understood and can be addressed with higher dosing in Cohort 2 [#8-K-2026-05-07]. If that explanation holds, the May 7 selloff may have overshot the remaining platform option value.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.5.
What can break
Cash runway extends only into Q3 2027, while Q1 2026 net loss was $39.7 million and collaboration revenue fell sharply year over year, so any meaningful delay or weak follow-up data could revive financing risk [#8-K-2026-05-07].
Momentum
10
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.50 · Bull $11.00 · Bear $4.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $16.67
Why
Momentum10 · Δ7d +2.1
Value41 · Δ7d +0.0
Sentiment60 · Δ7d -3.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
10
26% active weight
Current posture
7d trendImproving
Δ7d
+2.1
Δ21d
-0.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
60
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.5
Δ21d
+9.6
Why this grade
Composite grade F. Momentum 10.1 / Value 41.1 / Sentiment 59.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$246.12M
Beta
-0.12
Shares Out
38.82M
P/E (TTM) · Derived
-1.8
P/S (TTM)
6.52
P/FCF (TTM) · Derived
-2.00
Rev YoY
-95.7%
EPS YoY
+124.7%
Gross Margin
+30.4%
Op Margin
-197.6%
Net Debt
-$245.42M
Current Ratio
13.90
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology